In the latest session, Lexicon Pharmaceuticals Inc (NASDAQ: LXRX) closed at $2.17 up 0.93% from its previous closing price of $2.15. In other words, the price has increased by $+0.0200 from its previous closing price. On the day, 1278556 shares were traded. LXRX stock price reached its highest trading level at $2.2492 during the session, while it also had its lowest trading level at $2.1200.
Ratios:
For a deeper understanding of Lexicon Pharmaceuticals Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.91 and its Current Ratio is at 6.92. In the meantime, Its Debt-to-Equity ratio is 0.76 whereas as Long-Term Debt/Eq ratio is at 0.75.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Jefferies on March 07, 2023, initiated with a Hold rating and assigned the stock a target price of $3.
On August 12, 2022, Piper Sandler started tracking the stock assigning a Overweight rating and target price of $10.
JP Morgan Upgraded its Underweight to Neutral on January 29, 2021, while the target price for the stock was maintained at $7.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Nov 16 ’23 when COATS LONNEL bought 90,000 shares for $1.05 per share. The transaction valued at 94,797 led to the insider holds 914,359 shares of the business.
COATS LONNEL bought 10,000 shares of LXRX for $10,100 on Nov 10 ’23. The Chief Executive Officer now owns 824,359 shares after completing the transaction at $1.01 per share. On Oct 12 ’23, another insider, DEBBANE RAYMOND, who serves as the Director of the company, bought 148,820 shares for $1.03 each. As a result, the insider paid 153,805 and bolstered with 1,340,847 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, LXRX now has a Market Capitalization of 525.87M and an Enterprise Value of 413.45M. For the stock, the TTM Price-to-Sale (P/S) ratio is 1002.83 while its Price-to-Book (P/B) ratio in mrq is 3.82. Its current Enterprise Value per Revenue stands at 780.09 whereas that against EBITDA is -2.78.
Stock Price History:
Over the past 52 weeks, LXRX has reached a high of $3.79, while it has fallen to a 52-week low of $0.92. The 50-Day Moving Average of the stock is 2.0382, while the 200-Day Moving Average is calculated to be 1.7692.
Shares Statistics:
For the past three months, LXRX has traded an average of 3.96M shares per day and 3.56M over the past ten days. A total of 244.93M shares are outstanding, with a floating share count of 238.24M. Insiders hold about 2.73% of the company’s shares, while institutions hold 74.32% stake in the company. Shares short for LXRX as of Feb 15, 2024 were 23.41M with a Short Ratio of 5.91, compared to 25.27M on Jan 12, 2024. Therefore, it implies a Short% of Shares Outstanding of 9.59% and a Short% of Float of 15.94%.
Earnings Estimates
There are 4 different market analysts currently analyzing its stock. On average, analysts expect EPS of -$0.22 for the current quarter, with a high estimate of -$0.19 and a low estimate of -$0.24, while EPS last year was -$0.16. The consensus estimate for the next quarter is -$0.23, with high estimates of -$0.22 and low estimates of -$0.25.
Analysts are recommending an EPS of between -$0.74 and -$0.84 for the fiscal current year, implying an average EPS of -$0.8. EPS for the following year is -$0.78, with 4 analysts recommending between -$0.67 and -$0.93.
Revenue Estimates
A total of 4 analysts believe the company’s revenue will be $1.24M this quarter.It ranges from a high estimate of $2.1M to a low estimate of $600k. As of the current estimate, Lexicon Pharmaceuticals Inc’s year-ago sales were $28k, an estimated increase of 4,328.60% from the year-ago figure. For the next quarter, 3 analysts are estimating revenue of $1.89M, an increase of 7,775.00% over than the figure of $4,328.60% in the same quarter last year. There is a high estimate of $3.66M for the next quarter, whereas the lowest estimate is $1M.
A total of 4 analysts have provided revenue estimates for LXRX’s current fiscal year. The highest revenue estimate was $2.6M, while the lowest revenue estimate was $1.1M, resulting in an average revenue estimate of $1.74M. In the same quarter a year ago, actual revenue was $139k, up 1,151.80% from the average estimate. Based on 4 analysts’ estimates, the company’s revenue will be $33.22M in the next fiscal year. The high estimate is $48.94M and the low estimate is $13.6M. The average revenue growth estimate for next year is up 1,809.20% from the average revenue estimate for this year.
